When appropriate, surgery remains the most effective treatment option for non-small cell lung cancer (NSCLC), including for patients with COPD, said Friedberg, professor in the Department of Thoracic ...
Chronic obstructive pulmonary disease (COPD) remains a substantial contributor to morbidity and mortality in the United States with an estimated 3.8% age-adjusted prevalence and 141,733 COPD deaths ...
The primary finding from the clinical trials for the COPD biologics is reduced annual exacerbations by 30% (BOREAS trial) and 34% (NOTUS trial). In the BOREAS trial, in addition to reduced ...
This publication aims to improve treatment and care for adults with chronic obstructive pulmonary disease (COPD). It provides commissioners with strategies and recommendations for frontline care, ...
November is National Chronic Obstructive Pulmonary Disease Awareness Month. It’s time to raise awareness about lung disease within our communities. By understanding the causes, reducing our risk ...
The National Institute for Health and Care Excellence (NICE), has published final draft guidance recommending dupilumab as a ...
The U.S. Food and Drug Administration has approved GSK's Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease ...
Asthma and chronic obstructive pulmonary disease (COPD) are chronic respiratory (lung) diseases that cause breathing difficulty and coughing. Asthma affects about 28 million people in the United ...
Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will impact their patients. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results